In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis announces MOU to buy Advanced Accelerator Applications for $3.9bn; later tenders offer

Executive Summary

Confirming rumors that began circulating late last month, Novartis AG entered a memorandum of understanding (MOU) to tender an all-cash offer for all outstanding shares of public French biotech Advanced Accelerator Applications SA (AAA; diagnostic and therapeutic radiopharmaceuticals). The AAA board has already approved the MOU.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies